NHS Dudley Health Economy Medicines Formulary
Home > 4 Central nervous system > 4.11 Drugs for dementia > Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease - NICE TAG TA217

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease - NICE TAG TA217

This guidance has been partially updated by the NICE guideline on dementia. See about this guidance for more information.

1.1The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine are recommended as options for managing mild to moderate Alzheimer's disease under all of the conditions specified in 1.3 and 1.4.

1.2Memantine is recommended as an option for managing Alzheimer's disease for people with:

  • moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or

  • severe Alzheimer's disease. 

    Treatment should be under the conditions specified in 1.3.

1.3Treatment should be under the following conditions:

  • This recommendation has been updated and replaced by recommendation 1.6.2.3 in the NICE guideline on dementia.

  • Treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global, functional or behavioural symptoms.

  • This recommendation has been updated and replaced by recommendation 1.6.2.3 in the NICE guideline on dementia.

1.4If prescribing an AChE inhibitor (donepezil, galantamine or rivastigmine), treatment should normally be started with the drug with the lowest acquisition cost (taking into account required daily dose and the price per dose once shared care has started). However, an alternative AChE inhibitor could be prescribed if it is considered appropriate when taking into account adverse event profile, expectations about adherence, medical comorbidity, possibility of drug interactions and dosing profiles.

1.5When using assessment scales to determine the severity of Alzheimer's disease, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the results and make any adjustments they consider appropriate. Healthcare professionals should also be mindful of the need to secure equality of access to treatment for patients from different ethnic groups, in particular those from different cultural backgrounds.

1.6When assessing the severity of Alzheimer's disease and the need for treatment, healthcare professionals should not rely solely on cognition scores in circumstances in which it would be inappropriate to do so. These include:

  • if the cognition score is not, or is not by itself, a clinically appropriate tool for assessing the severity of that patient's dementia because of the patient's learning difficulties or other disabilities (for example, sensory impairments), linguistic or other communication difficulties or level of education or

  • if it is not possible to apply the tool in a language in which the patient is sufficiently fluent for it to be appropriate for assessing the severity of dementia or

  • if there are other similar reasons why using a cognition score, or the score alone, would be inappropriate for assessing the severity of dementia.

    In such cases healthcare professionals should determine the need for initiation or continuation of treatment by using another appropriate method of assessment.

  • http://www.nice.org.uk/guidance/TA217

 

Site by Devopa
© Copyright 2021 NHS. All rights reserved.